Articles by Joanna Breitstein - Pharmaceutical Executive


Articles by Joanna Breitstein

Thought Leader: Q&A with Hugo Stephenson

Patient-Run Trials
Mar 1, 2006

Companies don't have the budget, but are being forced to do more active surveillance.

Breath of Hope: TB in Africa

For the first time in decades, pharma has tuberculosis drugs in the pipeline. But it will take more than new pills to solve the problem. Executive Editor Joanna Breitstein reports from East Africa.
Feb 1, 2006

In The Small, Dusty, District Hospital In Temeke, Tanzania, head nurse Sarah Wilson Ochogo is carrying out her morning ritual. She drags a table outside the hospital's tuberculosis (TB) unit, sets out big, white, plastic bottles of pills, and opens a pencil-lined ledger that tracks her patients, their drugs, and their doses. By seven, more than 100 patients are lining up. They place their green patient cards under a stone near the table, and sit down on wooden benches to wait until Ochogo calls their name, gives them their medication, and watches while they take it. By a bit after nine, the patients are off to their daily routines—drawing water, tending crops, or just getting by the way people always have in Africa. And all of them, with luck, are one more day closer to curing their TB.

Weathering the Storm

Out from financial scandal, CEO Peter Dolan is steering BMS' most productive pipeline yet.
Aug 1, 2005

BMS' use of investigational toxicology puts it in good stead with FDA, which, under its Critical Path initiative, is pushing for more complete toxicology packages.

Turn the Page

Changes in ethics and expectations are driving the way pharma interacts with medical publishers.
Jun 1, 2005

When Jim Dougherty joined Mcgraw-Hill almost 30 years ago, medical journal publishing was just plain different than it is today. The days of the "three-martini lunch" were slowly coming to an end. Yet many companies still determined their ad schedules based on relationships. There was also less competition: without DTC or the Internet, journals garnered larger percentages of pharma's marketing mix. Today, Dougherty is group vice president of McGraw-Hill Healthcare Information and president of the Association of Medical Publications (AMP), an organization of publishing firms in the medical field. Like many of his peers, Dougherty has witnessed—and continues to witness—the transformation of the field. The future is bright, he says, but most certainly uncertain.

Pharm Exec Ad Stars

May 1, 2005

A review of the best ads of 2004--and the people that created them.

Eisai's New Leadership

Eisai's US president and COO Lonnel Coats, and chairman and CEO Hajime Shimizu, talk about their first year on the job.
May 1, 2005

I realized that, as president of a pharmaceutical company, I am now a representative of the entire industry. As such, my toughest challenge is listening to and seeing the kind of scrutiny our industry is taking.

AIDS in Africa: The Road Forward

Industry pioneers have already taken the first steps to address the AIDS crisis in Africa. But the fate of the millions infected—and those yet to be—lies in companies building upon the promise of their progress. This conclusion of Joanna Breitstein's report shows how they are working to craft tomorrow's models today.
Mar 1, 2005

If the Aspen model works, it could change the model for the developing world. Research-based companies could focus on R&D, and leave the manufacturing to generic companies.

Doctors Behind Bars

In some cases, going to jail may be a good thing.
Feb 1, 2005

There's no better use of healthcare marketing dollars than to reach patients with unmet needs. That's why niche marketing has gained steam during the last few years. But increasing competition in accessing doctors who treat culturally and racially diverse patient groups means pharma marketers have to refine their definition of what constitutes a niche market in the first place. In doing so, they may stumble over a market that has not yet been saturated—US prisoners.

AIDS IN AFRICA: The Lazarus Effect

Feb 1, 2005

For Africa's 25 million AIDS patients, the difference between death and life is drugs. But how do pharma's products get from the world's wealthiest companies to patients at the heart of the world's biggest health disaster? Joanna Breitstein went to Uganda to find out.


Click here